Past and future of neurotrophic growth factors therapies in ALS

From single neurotrophic growth factor to stem cells and human platelet lysates

Flore Gouel, Anne Sophie Rolland, Jean Christophe Devedjian, Thierry Burnouf, David Devos

Research output: Contribution to journalArticle

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that typically results in death within 3-5 years after diagnosis. To date, there is no curative treatment and therefore an urgent unmet need of neuroprotective and/or neurorestorative treatments. Due to their spectrum of capacities in the central nervous system-e.g., development, plasticity, maintenance, neurogenesis-neurotrophic growth factors (NTF) have been exploited for therapeutic strategies in ALS for decades. In this review we present the initial strategy of using single NTF by different routes of administration to the use of stem cells transplantation to express a multiple NTFs-rich secretome to finally focus on a new biotherapy based on the human platelet lysates, the natural healing system containing a mix of pleitropic NTF and having immunomodulatory function. This review highlights that this latter treatment may be crucial to power the neuroprotection and/or neurorestoration therapy requested in this devastating disease.

Original languageEnglish
Article number835
JournalFrontiers in Neurology
Volume10
Issue numberJUL
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Nerve Growth Factors
Amyotrophic Lateral Sclerosis
Intercellular Signaling Peptides and Proteins
Stem Cells
Blood Platelets
Therapeutics
Biological Therapy
Neurogenesis
Stem Cell Transplantation
Neurodegenerative Diseases
Central Nervous System
Maintenance

Keywords

  • Amyotrophic lateral sclerosis
  • Growth factors
  • Human platelet lysate
  • Stem cell
  • Therapeutic

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Past and future of neurotrophic growth factors therapies in ALS : From single neurotrophic growth factor to stem cells and human platelet lysates. / Gouel, Flore; Rolland, Anne Sophie; Devedjian, Jean Christophe; Burnouf, Thierry; Devos, David.

In: Frontiers in Neurology, Vol. 10, No. JUL, 835, 01.01.2019.

Research output: Contribution to journalArticle

@article{30d5411e3960468393ff7317498b2fed,
title = "Past and future of neurotrophic growth factors therapies in ALS: From single neurotrophic growth factor to stem cells and human platelet lysates",
abstract = "Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that typically results in death within 3-5 years after diagnosis. To date, there is no curative treatment and therefore an urgent unmet need of neuroprotective and/or neurorestorative treatments. Due to their spectrum of capacities in the central nervous system-e.g., development, plasticity, maintenance, neurogenesis-neurotrophic growth factors (NTF) have been exploited for therapeutic strategies in ALS for decades. In this review we present the initial strategy of using single NTF by different routes of administration to the use of stem cells transplantation to express a multiple NTFs-rich secretome to finally focus on a new biotherapy based on the human platelet lysates, the natural healing system containing a mix of pleitropic NTF and having immunomodulatory function. This review highlights that this latter treatment may be crucial to power the neuroprotection and/or neurorestoration therapy requested in this devastating disease.",
keywords = "Amyotrophic lateral sclerosis, Growth factors, Human platelet lysate, Stem cell, Therapeutic",
author = "Flore Gouel and Rolland, {Anne Sophie} and Devedjian, {Jean Christophe} and Thierry Burnouf and David Devos",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fneur.2019.00835",
language = "English",
volume = "10",
journal = "Frontiers in Neurology",
issn = "1664-2295",
publisher = "Frontiers Research Foundation",
number = "JUL",

}

TY - JOUR

T1 - Past and future of neurotrophic growth factors therapies in ALS

T2 - From single neurotrophic growth factor to stem cells and human platelet lysates

AU - Gouel, Flore

AU - Rolland, Anne Sophie

AU - Devedjian, Jean Christophe

AU - Burnouf, Thierry

AU - Devos, David

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that typically results in death within 3-5 years after diagnosis. To date, there is no curative treatment and therefore an urgent unmet need of neuroprotective and/or neurorestorative treatments. Due to their spectrum of capacities in the central nervous system-e.g., development, plasticity, maintenance, neurogenesis-neurotrophic growth factors (NTF) have been exploited for therapeutic strategies in ALS for decades. In this review we present the initial strategy of using single NTF by different routes of administration to the use of stem cells transplantation to express a multiple NTFs-rich secretome to finally focus on a new biotherapy based on the human platelet lysates, the natural healing system containing a mix of pleitropic NTF and having immunomodulatory function. This review highlights that this latter treatment may be crucial to power the neuroprotection and/or neurorestoration therapy requested in this devastating disease.

AB - Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that typically results in death within 3-5 years after diagnosis. To date, there is no curative treatment and therefore an urgent unmet need of neuroprotective and/or neurorestorative treatments. Due to their spectrum of capacities in the central nervous system-e.g., development, plasticity, maintenance, neurogenesis-neurotrophic growth factors (NTF) have been exploited for therapeutic strategies in ALS for decades. In this review we present the initial strategy of using single NTF by different routes of administration to the use of stem cells transplantation to express a multiple NTFs-rich secretome to finally focus on a new biotherapy based on the human platelet lysates, the natural healing system containing a mix of pleitropic NTF and having immunomodulatory function. This review highlights that this latter treatment may be crucial to power the neuroprotection and/or neurorestoration therapy requested in this devastating disease.

KW - Amyotrophic lateral sclerosis

KW - Growth factors

KW - Human platelet lysate

KW - Stem cell

KW - Therapeutic

UR - http://www.scopus.com/inward/record.url?scp=85070792035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070792035&partnerID=8YFLogxK

U2 - 10.3389/fneur.2019.00835

DO - 10.3389/fneur.2019.00835

M3 - Article

VL - 10

JO - Frontiers in Neurology

JF - Frontiers in Neurology

SN - 1664-2295

IS - JUL

M1 - 835

ER -